ORIGINAL COMMUNICATION
|
|
- Chastity Campbell
- 6 years ago
- Views:
Transcription
1 (2004) 58, & 2004 Nature Publishing Group All rights reserved /04 $ ORIGINAL COMMUNICATION Calcium and vitamin D 3 supplements in calcium and vitamin D 3 sufficient early postmenopausal healthy women J Tfelt-Hansen 1 and O Tørring 1,2 * 1 Department of Endocrinology PE, Copenhagen University Hospital, Rigshospitalet, Denmark; and 2 Division of Endocrinology, Department of Medicine and Karolinska Institutet at Södersjukhuset, Stockholm, Sweden Objective: To study the calcium homeostasis in healthy, calcium and vitamin D replete early postmenopausal women during oral supplementation with calcium and vitamin D 3. Design: A prospective, placebo-controlled, randomised, double-single-blind, 3-week study. Setting: Outpatient clinic at Copenhagen University Hospital, Denmark. Subjects: In all, 17 started, one was excluded. Totally, 16 healthy women, y of age (mean 57.3 y) who were at least 4 y after menopause (mean 6.7 y) completed. Interventions: All underwent three consecutive 7-day study periods. Each began with 4 days of normal diet followed by 3 days treatment of either C: one tablet of mg calcium carbonate (ie 500 mg Ca 2 þ per tablet) twice daily (breakfast and dinner), or CD 3 : as in C but plus 400 IU vitamin D 3 b.i.d., or P (only) placebo tablets b.i.d. Results: At baseline plasma 25-hydroxycholecalciferol was normal (66722 nmol/l) and the calcium intake without supplements 850 mg/day. In group C, the 24-h urinary calcium increased by 35% ( mmol), vs the placebo group P ( mmol) (Po0.05). Addition of 800 IU vitamin D 3 daily (CD 3 ) did not increase calcium excretion further ( mmol) but decreased plasma 1,25-(OH) 2 -vitamin D 3 by 21% (Po0.05). Conclusions: In this carefully controlled study calcium plus vitamin D 3 supplements only had minor influences of uncertain significance on the calcium balance in healthy, calcium and vitamin D sufficient early postmenopausal women. Sponsorship: Copenhagen University, Karolinska Institutet and Nycomed A/S. (2004) 58, doi: /sj.ejcn Published online 28 April 2004 Keywords: calcium metabolism; vitamin D; postmenopausal women; cholecalciferol; Ca 2 þ ; 1,25(OH) 2 D 3 ; PTH Introduction Adequate intakes of calcium and vitamin D are essential for skeletal growth and prevention of osteoporosis. A considerable number of elderly women, however, have biochemical indications of calcium and vitamin D deficiency (Lips, 1991; McKenna, 1992; Melin et al, 1999). Supplements may improve calcium balance, prevent secondary hyperparathyroidism, postpone bone loss and reduce the risk of osteoporotic *Correspondence: Dr O Tørring, Chief of Division of Endocrinology, Department of Medicine, C7, Karolinska Institutet, Södersjukhuset, S Stockholm, Sweden. ove.tørring@sos.sll.se Guarantor: O Tørring. Sources of support: Nycomed DK-4000 Roskilde, Denmark Received 7 May 2003; revised 9 March 2004; accepted 16 March 2004; published online 28 April 2004 fractures (Aida et al, 1995; Chapuy et al, 1992, 1994; Francis et al, 1996; Ooms et al, 1995;Tilyardet al, 1992).Postmenopausal women without hormone replacement therapy are recommended daily dietary intakes of mg calcium and 800 IU vitamin D, recommendations that may be difficult to be met with a normal diet (NIH Consensus Statement, 1994; Physician s guide to prevention and treatment of osteoporosis, 2000; Rasmussen et al, 2000). Many women therefore start taking calcium and vitamin D 3 supplements soon after the menopause in order to prevent early osteoporosis. During the first 2 4 y after menopause, these supplements, however, have no significant effect on bone mass mainly due to an increased bone turnover and net output of calcium from the skeleton caused by diminishing oestrogen concentration (Dawson- Hughes et al, 1990). The question is does vitamin D supplementation have any advantage over calcium supplementation
2 in healthy, calcium- and vitamin D-sufficient early postmenopausal women with regard to calcium homeostasis? Commercial calcium supplements are available as various salts, for example, carbonate, phosphates, citrate and bone powder. Bioavailability of calcium is between 20 and 40% in these supplements and varies with the salt and the formulation. Bioavailability is approximately 32 35% for calcium carbonate, which is the most frequently used source of calcium and the most cost effective, containing 40% Ca 2 þ (Heaney et al, 1990). Calcium balance can be estimated with various methods: determination of oral intake minus combined urinary, fecal and dermal losses, with radioactive or stable isotopic tracer or by metabolic changes after oral calcium load (Zerwekh et al, 1981). The first method is cumbersome and not very precise. Isotopic tracers are restricted in use in Denmark due to legislation. Whenever a calcium supplement is investigated in short-term studies, metabolic methods such as urine calcium excretion and changes in plasma PTH are therefore preferred (Tørring et al, 1985; Tfelt-Hansen et al, 2001). In the present study, 24 h urinary calcium excretion was used as indicator of calcium absorption in the group of healthy, early postmenopausal women consuming an omnivorous diet and having normal plasma 25-hydroxy-cholecalciferol (25(OH)D 3 ). Subjects and methods Subjects In all, 17 women were included of which one was erroneously randomized since her hypertension was overseen. She therefore was excluded from the study. Totally, 16 healthy women completed the study. Mean age was y (52 61 y), mean body weight kg (55 94 kg) and mean Body mass index kg/m 2. Years after menopause (last period) was y (mean7s.d.) (range 4 11 y). All participants were recruited through announcements on bulletin boards and in the newsletter of the hospital or among the hospital staff or their friends and all had some connection with the healthcare system and were familiar with collection of urine, diet control etc. The inclusion criteria were: Signed informed consent, female, age y, with menopause 4 y prior and a normal, common Danish diet (omnivorous). Exclusion criteria included significant diseases including hypertension, treatment with corticosteroids, hormone replacement therapy, intake of drugs known to influence calcium metabolism, current use of supplements with calcium and/or vitamin D 3 (4200 IU/day), coffee consumption above 1 l daily and a dietary calcium intake below 600 mg daily. Diet At 1 3 weeks before inclusion, all subjects were interviewed by an certified and experienced dietician about their diet and intake of calcium and vitamin D. They were instructed to keep a normal diet with a calcium intake of mg daily. The mean calcium intake was mg at screening and mg at entry. Three subjects increased their calcium intake to comply with the entry criterion and six reduced. The dietary vitamin D intake was judged by our dietician after interviewing each subject to be normal in all which is also reflected in normal baseline 25(OH)-vitamin D 3 levels (Table 2). Study design and test treatment Placebo-controlled, randomized, double-single blind and cross-over with three test treatments: 1. Calcium (C): 500 mg calcium tablets (as mg CaCO 3, Calcium s chewable tablets, Nycomed, Denmark). 2. Calcium plus vitamin D 3 (CD 3 ): as C plus 400 IU vitamin D 3 (10-mg cholecalciferol) (CaviD s chewable tablets, Nycomed, Denmark). 3. Placebo (P): tablets with identical appearance taste and content of vehicle (lactose, cellulose and sorbitol) as C and CD 3. The test dosage was two tablets daily taken: one with breakfast and one with the evening meal. The three 7-day study periods began with 4 days of normal diet (washout) followed by 3 days of test treatment. In order to avoid any carry-over effects of vitamin D 3 from CD 3 to the other periods, subjects started with either C or P according to randomization followed by CD 3. Neither investigator nor subject knew when C or P was given during the first 2 weeks (doubleblind) whereas only subjects were blind during the third week in which CD 3 was given (single-blind). Investigators controlled intake of test treatment, at the end of each week. Laboratory analyses Blood. Samples were drawn from a cubital vein at days 0, 8, 15 and 22. Serum was analyzed immediately for Ca 2 þ with a calcium-ion selective electrode (ICA II s, Radiometer A/S, Þ, creatinine and total alkaline phosphatase (ALP) with routine methods (Hitachi 917 s ). The following plasma analyses were done after the study and at the same time to minimize interassay coefficients of variation: Intact parathyroid hormone (1-84) (PTH) with a two-site RIA (Nichols Institute, CA, USA), 25 hydroxycholecalciferol and 1,25-dihydroxy-cholecalciferol (1,25(OH) 2 vit D) (days 0, 15 and 22) with RIA performed by a ISO 9000 certified commercial laboratory (Medilab, Copenhagen). Denmark) and for phosphate ðpo 3 4 Urine. Three consecutive 24-h collections of urine started after the subject had emptied the bladder in the morning of the 5th day of each period, that is, on the first test treatment day. After each 24-h collection period the urine was acidified and kept cold and handed over to the hospital laboratory for analysis by routine methods (Hitachi 917 s ) for each day separately. Only one urine sample of 144 ml was lost during the study. The study took place from early September to late November at Rigshospitalet, The Copenhagen University 1421
3 1422 Hospital, Denmark situated at latitude 55.61N. It was approved by the National Board of Health and the Ethics Committee of Copenhagen and performed according to the Declaration of Helsinki II version 1996 and ICH Good Clinical Practice (ICH-harmonised Tripartite Guidelines for Good Clinical Practice, 1996; World Medical Association Declaration of Helsinki 1964). Statistics The primary end point, that is, 24-h urinary calcium excretion, was tested with parametric analysis of variance (ANOVA). The hypothesis tested was whether the total amount of calcium excreted was equal for the three kinds of study medications. The 95% confidence interval for pairwise comparison of treatments was calculated by Scheffe s method for multiple comparisons. Additional laboratory variables served as secondary end points and were summarized using descriptive statistics. The significance level was set at 5%. All variables were inspected by means of QQ plots, histograms and Anderson Darling tests of the normal distribution assumption (using PROC CAP- ABILITY of SAS s System for Windows, Release 6.12). Results are presented as mean 7 s.d. and range. Since there are no significant differences between results for the intention to treat (ITT) population (n ¼ 17) and the per protocol (PP) population, that is, the number of subjects who completed the study and who were included in the efficacy analyses (n ¼ 16), PP data are presented here. Results The 24-h urinary calcium excretion increased by 35% ( mmol for C vs mmol for P) (Po0.05). The addition of 800 U of cholecalciferol during the 3 days (CD 3 ) did not increase the calcium excretion further (Table 1). The difference between group C and CD 3 was insignificant. The 24-h phosphate excretion was lower for group C ( mmol) compared to group P ( mmol) (Po0.05) but no difference between group CD 3 and group P and C was observed (Table 1). There was a 21% significant reduction in 1,25(OH) 2 vitamin D 3 from pmol/l at baseline to pmol/l at day 22 (Po0.05) whereas 25(OH)D 3 was unchanged in group CD 3 (Table 2). The concentrations of plasma Ca 2 þ, phosphate, PTH, creatinine and ALP did not change substantially during the three study periods (Table 2). Eight subjects reported a total of 10 adverse events that were all mild. Three subjects reported constipation, whereas the following events were reported by one subject: pain in the neck, migraine, diarrhoea, increased diuresis, palpitations, dry mouth and a tic bite. Compliance with intake of test treatment drugs (pill counting) and the study procedures was 100% (except for one lost urine sample). Discussion Calcium supplements are widely used by women at the menopause and thereafter to prevent osteoporosis. The benefits of calcium supplement to women early after menopause who are in a good nutritional status with respect to calcium and vitamin D are uncertain. During the first 2 3 y after menopause, the bone turnover is increased due to lack of oestrogen leading to increased excretion of calcium in the urine during this period. Calcium supplements are considered of limited value at least for the prevention of osteoporosis during this period. Table 1 24-h excretion of calcium, phosphate and creatinine in urine after oral supplement with 1000 mg calcium without (group C) or combined with 800 IU vitamin D3 per day (CD3) or placebo (P) for 3 days in 16 early postmenopausal healthy women on a calcium and vitamin D sufficient diet Group U-Ca (mmol) U-phosphate (mmol) U-creatinine (mmol) C (calcium only) 6.9* * CD 3 (calcium þ vitamin D 3 ) 6.6* P (placebo) * Po0.05 compared to placebo; (mean7s.d.). The values are the mean of three consecutive 24-h urine samples collected the last 3 days of each 1 week period. Table 2 Plasma concentrations of laboratory variables at baseline and after test treatments Day Ca 2 þ P PTH Creatinine ALP 25(OH)D 3 1,25(OH) 2 D 3 Baseline P, placebo 8/ NA NA C, calcium 15/ NA NA CD 3, calcium þ vitamin D *719 Reference interval Unit mmol/l mmol/l pmol/l mmol/l U/l nmol/l pmol/l * NA: not applicable; *Po0.05 compared to baseline; mean7s.d.
4 We did not measure bone markers but selected women who were at least four years after menopause to have as homogenous an early postmenopausal group of women with respect to calcium homeostasis as possible. However, other investigators have found no significant effects on markers of bone turnover of oral supplementation with 800 IU cholecalciferol daily for 2 years in postmenopausal women in a well-controlled twin-study in the UK (Hunter et al, 2000). Furthermore, vitamin D supplementation to early postmenopausal women had no significant positive effect on lumbar spine bone loss compared with placebo during a 5- y randomized trial in Finland (Komulainen et al, 1999). The calcium intake on average (1019 mg) in the present study subjects was close to that recommended at the time of screening for the study but showed a rather broad variation. After a slight dietary adjustment by the dietician the average calcium intake at start of study was quite homogenous around 862 mg and was kept constant during the study. The adjustment was done to minimize the risk of random and large variation in the calcium and phosphate excretion in the urine during the study. Under these circumstances and in vitamin D sufficient healthy subjects with a normal renal function we regard the 24-h calcium excretion as a fair estimate of the calcium absorption. Daily supplement of 1000 mg calcium carbonate increased the 24-h calcium excretion by 35%. The decrease in the phosphate excretion could indicate a transient suppression of the PTH-effect on the renal tubular reabsorption of phosphate. The plasma PTH concentrations were within the normal reference range and we did not see a substantial decrease in plasma PTH levels. This, however, could be due to the h period between last intake of calcium carbonate and the time for blood sampling next morning since the suppressive effect of an equivalent oral calcium load on plasma PTH concentration in short-term study occurs within 60 min (Tfelt-Hansen et al, 2001). We did not find a significant increase in calcium absorption by addition of 800 U cholecalciferol daily (group CD 3 ) compared with calcium carbonate alone which corroborates the results from another Danish study (Mortensen & Charles, 1996). Firstly, the majority of calcium absorption occurs in the duodenum through an active, regulated transport. Only a minor part occurs through a passive, paracellular pathway throughout the small intestine. The active calcium absorption is regulated by 1,25 (OH) 2 vit D 3 through its activating of intranuclear receptors followed by genomic upregulation of calbindin mrna expression and protein production in a matter of hours to days. In addition, 1,25 (OH) 2 vit D 3 also activates novel-specific membrane associated rapid response steroid binding proteins and thereby also excerts nongenomic effects within minutes (Kerstetter & O Brian, 2002). Contrary to the direct genomic and nongenomic effects of 1,25 (OH) 2 vit D 3, no such effects has been demonstrated for 25 (OH) 2 vit D 3. It is therefore unlikely that 800 U cholecalciferol daily as we used in the present study would increase the calcium absorption on short term. Secondly and more important, the study subjects were already in a good vitamin D nutritional status at the beginning of the study as judged by the normal serum concentrations of 25 (OH) 2 vit D 3, alkaline phosphatase, PTH and Ca 2 þ at baseline as well as unchanged plasma 25-hydroxyvitamin D 3 levels despite the supplementation. The study was performed from September to early November, that is, the season where we have the highest concentrations of plasma 25-hydroxyvitamin D 3 in Denmark. To avoid seasonal variations in vitamin D production, we concentrated the study to the early autumn to limit the number of confounding factors. It is therefore possible that the results would have been different if the study had been carried out during the winter or spring season since Copenhagen is located at 55.61N and the production of vitamin D precursors in the skin due to the UVB-radiation from the sun is almost absent from October to April above latitude 521N (Dawson et al, 1997). Another, hypothetical explanation of the lack of a clear effect of cholecalciferol is that variations in protein intake may have caused random variations in the calcium excretion and thus blur the results. A threefold increase in protein intake is reported to increase urinary calcium excretion and upregulate intestinal calcium absorption by around 50% (Farach-Carson & Nemere, 2003). In the present study, the subject were instructed to keep a normal diet with a relative constant calcium intake but no restrictions or guidance concerning the protein intake were given. This possibility, therefore, cannot be ruled out but according to our dietician none of the participants had excessive variation in the protein intake. Some effect of the vitamin D supplement did we, however, see, as the plasma calcitriol concentrations were 21% lower at the end of the CD 3 period, although within the normal reference range. Again this could be due to a transient suppression of PTH leading to a diminished 1-alpha vitamin D 3 hydroxylase activity in the kidney. The slightly lower phosphate excretion also supports this view but we did not follow the plasma PTH sufficiently frequent to support this firmly. From this well-controlled study, we conclude that supplementation with calcium and vitamin D in healthy women who are early after their menopause and who already eat an calcium and vitamin-d sufficient diet only have minor influences on the calcium metabolism. Acknowledgements We wish to thank the staff at the department of nephrology, especially Bente Spon, Betty Fisher and Kirsten Andersen for excellent help and support. References Aida K, Koishi S, Tawata M & Onaya T (1995): Molecular cloning of a putative Ca(2 þ )-sensing receptor cdna from human kidney. Biochem. Biophys. Res. Commun. 214,
5 1424 Chapuy MC, Arlot ME, Delmas PD & Meunier PJ (1994): Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. Br.Med.J. 308, Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, Delmas PD & Meunier PJ (1992): Vitamin D3 and calcium to prevent hip fractures in the elderly women. N. Engl. J. Med. 327, Dawson HB, Harris SS & Dallal GE (1997): Plasma calcidiol, season, and serum parathyroid hormone concentrations in healthy elderly men and women. Am. J. Clin. Nutr. 65, Dawson-Hughes B, Dallal GE, Krall EA, Sadowski L, Sahyoun N & Tannenbaum S (1990): A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. N. Engl. J. Med. 323, Farach-Carson MC & Nemere I (2003): Membrane receptors for vitamin D steroid hormones: potential new drug targets. Curr. Drug Targets 4, Francis RM, Boyle IT, Moniz C, Sutcliffe AM, Davis BS, Beastall GH, Cowan RA & Downes N (1996): A comparison of the effects of alfacalcidol treatment and vitamin D2 supplementation on calcium absorption in elderly women with vertebral fractures. Osteoporos. Int. 6, Heaney RP, Recker RR & Weaver CM (1990): Absorbability of calcium sources: the limited role of solubility. Calcif. Tissue Int. 46, Hunter D, Major P, Arden N, Swaminathan R, Andrew T, MacGregor AJ, Keen R, Snieder H & Spector TD (2000): A randomized controlled trial of vitamin D supplementation on preventing postmenopausal bone loss and modifying bone metabolism using identical twin pairs. J. Bone Miner. Res. 15, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) adopts Consolidated Guideline on Good Clinical Practice in the Conduct of Clinical Trials on Medicinal Products for Human Use (1997): International Digest of Health Legislation. 48 (2), Kerstetter JE, O Brian KO & Insogna KL (2002): Dietary protein, calcium metabolism, and skeleton homeostasis revisited. Am. J. Clin. Nutr. 78, 584S 592S. Komulainen M, Kroger H, Tuppurainen MT, Heikkinen AM, Alhava E, Honkanen R, Jurvelin J & Saarikoski S (1999): Prevention of femoral and lumbar bone loss with hormone replacement therapy and vitamin D3 in early postmenopausal women: a population-based 5-year randomized trial. J. Clin. Endocrinol. Metab. 84, Lips P (1991): The pathogenesis and treatment of hip fractures. Osteoporos. Int. 1, McKenna MJ (1992): Differences in vitamin D status between countries in young adults and the elderly. Am. J. Med 93, Melin AL, Wilske J, Ringertz H & Saaf M (1999): Vitamin D status, parathyroid function and femoral bone density in an elderly Swedish population living at home. Aging. 11, Mortensen L & Charles P (1996): Bioavailability of calcium supplements and the effect of Vitamin D: comparisons between milk, calcium carbonate, and calcium carbonate plus vitamin D. Am. J. Clin. Nutr. 63, NIH Consensus Statement (1994): Optimal Calcium Intake. Washington, USA: NIH. P 12. Ooms ME, Roos JC, Bezemer PD, van de V, Bouter LM & Lips P (1995): Prevention of bone loss by vitamin D supplementation in elderly women: a randomized double-blind trial. J. Clin. Endocrinol. Metab. 80, Physicican s guide to prevention and treatment of osteoporosis (2000): National Osteoporosis Foundation. Washington DC, USA ( Rasmussen LB, Hansen GL, Hansen E, Koch B, Mosekilde L, Molgaard C, Sorensen OH & Ovesen L (2000): Vitamin D: should the supply in the Danish population be increased? Int. J. Food. Sci. Nutr. 51, Tfelt-Hansen J, Schwarz P & Tørring O (2001): PTH and ionized calcium changes to oral calcium and D-vitamins in healthy premenopausal women. Scand. J. Clin. Lab. Invest. 61, Tilyard MW, Spears GF, Thomson J & Dovey S (1992): Treatment of postmenopausal osteoporosis with calcitriol or calcium. N. Engl. J. Med. 326, Tørring O, Bucht E & Sjoberg HE (1985): Plasma calcitonin response to a calcium clamp. Influence of sex and age. Horm. Metab. Res. 17, World Medical Association Declaration of Helsinki (1964). Zerwekh JE, Sakhaee K & Pak CY (1981): Utility and limitation of calciuric response to oral calcium load as a measure of intestinal calcium absorption: comparison with isotopic fractional calcium absorption. Invest. Urol. 19,
Vitamin D. Vitamin functioning as hormone. Todd A Fearer, MD FACP
Vitamin D Vitamin functioning as hormone Todd A Fearer, MD FACP Vitamin overview Vitamins are organic compounds that are essential in small amounts for normal metabolism They are different from minerals
More informationAnnie WC Kung, Keith DK Luk, LW Chu, and Peter KY Chiu
Age-related osteoporosis in Chinese: an evaluation of the response of intestinal calcium absorption and calcitropic hormones to dietary calcium deprivation 1 3 Annie WC Kung, Keith DK Luk, LW Chu, and
More informationThe Skeletal Response to Aging: There s No Bones About It!
The Skeletal Response to Aging: There s No Bones About It! April 7, 2001 Joseph E. Zerwekh, Ph.D. Interrelationship of Intestinal, Skeletal, and Renal Systems to the Overall Maintenance of Normal Calcium
More informationCalcium Nephrolithiasis and Bone Health. Noah S. Schenkman, MD
Calcium Nephrolithiasis and Bone Health Noah S. Schenkman, MD Associate Professor of Urology and Residency Program Director, University of Virginia Health System; Charlottesville, Virginia Objectives:
More informationVitamin D Status of an Outpatient Clinic Population
Calcif Tissue Int (2001) 69:263 267 DOI: 10.1007/s002230010054 2001 Springer-Verlag New York Inc. Vitamin D Status of an Outpatient Clinic Population L. Margiloff, 1 S. S. Harris, 2 S. Lee, 3 R. Lechan,
More informationTHE NEW ZEALAND MEDICAL JOURNAL
THE NEW ZEALAND MEDICAL JOURNAL Vol 116 No 1179 ISSN 1175 8716 Efficacy of an oral, 10-day course of high-dose calciferol in correcting vitamin D deficiency Fiona Wu, Toni Staykova, Anne Horne, Judy Clearwater,
More informationBAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008
BAD TO THE BONE Peter Jones, Rheumatologist QE Health, Rotorua GP CME Conference Rotorua, June 2008 Agenda Osteoporosis in Men Vitamin D and Calcium Long-term treatment with Bisphosphonates Pathophysiology
More informationBMD: A Continuum of Risk WHO Bone Density Criteria
Pathogenesis of Osteoporosis Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis AGING MENOPAUSE OTHER RISK FACTORS RESORPTION > FORMATION Bone Loss LOW PEAK BONE MASS Steven T Harris
More informationVitamin D and Calcium
Vitamin D and Calcium American Association of Clinical Endocrinologists Marina Del Rey, CA September 15, 2018 Albert Shieh, MD MS Assistant Clinical Professor Department of Medicine Division of Endocrinology
More informationThe Role of the Laboratory in Metabolic Bone Disease
The Role of the Laboratory in Metabolic Bone Disease Howard Morris PhD, FAACB, FFSc(RCPA) President, IFCC Professor of Medical Sciences, University of South Australia, Clinical Scientist, SA Pathology
More informationElecsys bone marker panel. Optimal patient management starts in the laboratory
bone marker panel Optimal patient management starts in the laboratory Complete solution for osteoporosis The most complete bone metabolism panel on a single platform bone marker assays are important diagnostic
More informationCALCIUM INTAKE MAY be one of the many factors that
0021-972X/05/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 90(2):707 711 Printed in U.S.A. Copyright 2005 by The Endocrine Society doi: 10.1210/jc.2004-1380 Lack of Effect of Calcium Intake
More informationBenefits of Calcium and Vitamin D: Building and Maintaining Healthy Bones
Benefits of Calcium and Vitamin D: Building and Maintaining Healthy Bones Prepared by Annette Dickinson, Ph.D. Council for Responsible Nutrition June 2002 There is no question that a generous intake of
More informationSouthern Derbyshire Shared Care Pathology Guidelines. Primary Hyperparathyroidism
Southern Derbyshire Shared Care Pathology Guidelines Primary Hyperparathyroidism Please use this Guideline in Conjunction with the Hypercalcaemia Guideline Definition Driven by hyperfunction of one or
More informationThe health economics of calcium and vitamin D3 for the prevention of osteoporotic hip fractures in Sweden Willis M S
The health economics of calcium and vitamin D3 for the prevention of osteoporotic hip fractures in Sweden Willis M S Record Status This is a critical abstract of an economic evaluation that meets the criteria
More informationNatpara (parathyroid hormone) Prior Authorization with Quantity Limit Program Summary
Natpara (parathyroid hormone) Prior Authorization with Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1 Agent Indication Dosing and Administration Natpara (parathyroid hormone) subcutaneous
More informationEfficacy of different doses and time intervals of oral vitamin D supplementation with or without calcium in elderly nursing home residents
Osteoporos Int (2008) 19:663 671 DOI 10.1007/s00198-007-0465-2 ORIGINAL ARTICLE Efficacy of different doses and time intervals of oral vitamin D supplementation with or without calcium in elderly nursing
More informationRobin M Daly, Nicole Petrass, Shona Bass, and Caryl A Nowson
The skeletal benefits of calcium- and vitamin D 3 fortified milk are sustained in older men after withdrawal of supplementation: an 18-mo follow-up study 1 3 Robin M Daly, Nicole Petrass, Shona Bass, and
More informationCalcium metabolism and the Parathyroid Glands. Calcium, osteoclasts and osteoblasts-essential to understand the function of parathyroid glands
Calcium metabolism and the Parathyroid Glands Calcium, osteoclasts and osteoblasts-essential to understand the function of parathyroid glands Calcium is an essential element for contraction of voluntary/smooth
More informationCKD: Bone Mineral Metabolism. Peter Birks, Nephrology Fellow
CKD: Bone Mineral Metabolism Peter Birks, Nephrology Fellow CKD - KDIGO Definition and Classification of CKD CKD: abnormalities of kidney structure/function for > 3 months with health implications 1 marker
More informationOMICS Journals are welcoming Submissions
OMICS Journals are welcoming Submissions OMICS International welcomes submissions that are original and technically so as to serve both the developing world and developed countries in the best possible
More informationThe New England Journal of Medicine EFFECT OF CALCIUM AND VITAMIN D SUPPLEMENTATION ON BONE DENSITY IN MEN AND WOMEN 65 YEARS OF AGE OR OLDER
EFFECT OF CALCIUM AND VITAMIN D SULEMENTATION ON BONE DENSITY IN MEN AND WOMEN 65 YEARS OF AGE OR OLDER BESS DAWSON-HUGHES, M.D., SUSAN S. HARRIS, D.SC., ELIZABETH A. KRALL, H.D., AND GERARD E. DALLAL,
More informationV t i amin i n D a nd n d Calc l iu i m u : Rol o e l in i n Pr P eve v nt n io i n and n d Tr T eatment n of o Fr F actur u es and n d Fa F ll l s
Vitamin D and Calcium: Role in Prevention and Treatment of Fractures and Falls Osteoporosis 21: New Insights In Research, Diagnosis, and Clinical Care Deborah Sellmeyer, MD Director, Johns Hopkins Metabolic
More informationBone Health in Celiac Disease. Partha S. Sinha MD, PhD October 29 th, 2017
Bone Health in Celiac Disease Partha S. Sinha MD, PhD October 29 th, 2017 No Disclosures Objectives Recognize the mechanisms by which celiac disease can affect bone health Review what diagnostic tests
More informationClinician s Guide to Prevention and Treatment of Osteoporosis
Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening
More informationVitamin D Replacement ROCKY MOUNTAIN MEETING NOV 2013 BANFF W.COKE UNIVERSITY OF TORONTO
Vitamin D Replacement ROCKY MOUNTAIN MEETING NOV 2013 BANFF W.COKE UNIVERSITY OF TORONTO Disclosures: (Academic Mea Culpa) No financial conflicts I have no expertise re: Vitamin D. OBJECTIVES: 1) Review
More informationVitamin D for the Prevention of Osteoporotic Fractures
TITLE: Vitamin D for the Prevention of Osteoporotic Fractures AUTHOR: Jeffrey A. Tice, MD Assistant Professor of Medicine Division of General Internal Medicine Department of Medicine University of California
More informationObjectives. Polypharmacy Seminar. Causes of Polypharmacy. Polypharmacy 8/05/12. National Prescribing Curriculum Module
Polypharmacy Seminar Objectives On completion of this module you should be able to: state the major guiding principles in rational prescribing recognise, and substantiate, over-prescribing or inappropriate
More informationJOURNAL OF INTERNATIONAL ACADEMIC RESEARCH FOR MULTIDISCIPLINARY Impact Factor 1.393, ISSN: , Volume 2, Issue 7, August 2014
HYPOVITAMINOSIS D IN INDIAN FEMALES WITH POSTMENOPAUSAL OSTEOPOROSIS DR. SHAH WALIULLAH 1 DR. VINEET SHARMA 2 DR. R N SRIVASTAVA 3 DR. YASHODHARA PRADEEP 4 DR. A A MAHDI 5 DR. SANTOSH KUMAR 6 1 Research
More informationEndocrine Regulation of Calcium and Phosphate Metabolism
Endocrine Regulation of Calcium and Phosphate Metabolism Huiping Wang ( 王会平 ), PhD Department of Physiology Rm C516, Block C, Research Building, School of Medicine Tel: 88208252 Email: wanghuiping@zju.edu.cn
More informationCa, Phos and Vitamin D Metabolism in Pre-Dialysis Patients
Ca, Phos and Vitamin D Metabolism in Pre-Dialysis Patients A. WADGYMAR, MD Credit Valley Hospital, Mississauga, Ontario, Canada. June 1, 2007 1 Case: 22 y/o referred to Renal Clinic Case: A.M. 29 y/o Man
More informationTREATMENT OF OSTEOPOROSIS
TREATMENT OF OSTEOPOROSIS Summary Prevention is the key issue in the management of osteoporosis. HRT is the agent of choice for prevention of postmenopausal osteoporosis. Bisphosphonates and Calcitonin
More informationThe efficacy of calcium supplementation alone in elderly Thai women over a 2-year period: a randomized controlled trial
Osteoporos Int () 4:87 877 DOI.7/s98-87-5 ORIGINAL ARTICLE The efficacy of calcium supplementation alone in elderly Thai women over a -year period: a randomized controlled trial R. Rajatanavin & L. Chailurkit
More informationnogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK
nogg NATIONAL OSTEOPOROSIS GUIDELINE GROUP Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Produced by J Compston, A Cooper,
More informationContinuing Education for Pharmacy Technicians Dietary Supplements: Calcium and Vitamin D
1 Continuing Education for Pharmacy Technicians Dietary Supplements: Calcium and Vitamin D Ashley Elliott, PharmD candidate Julie N. Bosler, PharmD McWhorter School of Pharmacy Birmingham, AL Objectives:
More informationDr Seeta Durvasula.
Dr Seeta Durvasula seeta.durvasula@sydney.edu.au 1 Avoid sun skin cancer risk Australia has highest rates of skin cancer in the world Epidemic of Vitamin D deficiency Lack of Vitamin D increases risk of
More informationPathway from Fracture or Risk Factor to Treatment
Appendix 6A - Guidance on Diagnosis and Management of Osteoporosis Pathway from Fracture or Risk Factor to Treatment Fragility Fracture = fracture sustained from a low energy fall from standing height
More informationDosage in renal impairment Kalcipos-D chewable tablets should not be used in patients with severe renal impairment.
SUMMARY OF THE PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Kalcipos-D 500 mg/400 IU chewable tablet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One chewable tablet contains: calcium 500 mg as
More informationIndex. B BMC. See Bone mineral content BMD. See Bone mineral density Bone anabolic impact, Bone mass acquisition
A Acid base balance dietary protein detrimental effects of, 19 Acid base balance bicarbonate effects, 176 in bone human studies, 174 mechanisms, 173 174 in muscle aging, 174 175 alkali supplementation
More informationEfficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study
Rheumatol Int (2006) 26: 427 431 DOI 10.1007/s00296-005-0004-4 ORIGINAL ARTICLE J. D. Ringe Æ H. Faber Æ P. Farahmand Æ A. Dorst Efficacy of risedronate in men with primary and secondary osteoporosis:
More informationThe Parathyroid Glands Secrete Parathyroid Hormone, which Regulates Calcium, Magnesium, and Phosphate Ion Levels
17.6 The Parathyroid Glands Secrete Parathyroid Hormone, which Regulates Calcium, Magnesium, and Phosphate Ion Levels Partially embedded in the posterior surface of the lateral lobes of the thyroid gland
More informationCa, Mg metabolism, bone diseases. Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary
Ca, Mg metabolism, bone diseases Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary Calcium homeostasis Ca 1000g in adults 99% in bones (extracellular with Mg, P) Plasma/intracellular
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationVITAMIN D IN HEALTH AND DISEASE
VITAMIN D IN HEALTH AND DISEASE Margus Lember University of Tartu, Estonia ESIM, Saas Fee, January 16, 2014 l It`s most healthy to live on the southern side of a mountain l Hippokrates of Kos 460-370 BC
More informationMEDICAL POLICY EFFECTIVE DATE: 08/21/14 REVISED DATE: 04/16/15, 06/16/16, 07/20/17 SUBJECT: SCREENING FOR VITAMIN D DEFICIENCY
MEDICAL POLICY SUBJECT: SCREENING FOR VITAMIN D DEFICIENCY A nonprofit independent licensee of the BlueCross BlueShield Association PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not
More informationAdditional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015. Dr.
Additional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015 Dr. Tessem Osteoporosis is a public health problem in all stages of life. Many
More informationPARATHYROID, VITAMIN D AND BONE
PARATHYROID, VITAMIN D AND BONE G M Kellerman Pathology North Hunter Service 30/01/2015 BIOLOGY OF BONE Bone consists of protein, polysaccharide components and mineral matrix. The mineral is hydroxylapatite,
More informationVitamin D and Calcium Therapy: how much is enough
Vitamin D and Calcium Therapy: how much is enough Daniel D Bikle, MD, PhD Professor of Medicine VA Medical Center and University of California San Francisco DISCLOSURE Nothing to disclose 1 RECOMMENDATIONS
More informationCalcium and Vitamin D Supplementation is an Ineffective Strategy for the Prevention of Fractures in Older People
Calcium and Vitamin D Supplementation is an Ineffective Strategy for the Prevention of Fractures in Older People For the Motion: Professor Roger Francis, Institute for Ageing and Health, Newcastle University,
More informationCoordinator of Post Professional Programs Texas Woman's University 1
OSTEOPOROSIS Update 2007-2008 April 26, 2008 How much of our BMD is under our control (vs. genetics)? 1 2 Genetic effects on bone loss: longitudinal twin study (Makovey, 2007) Peak BMD is under genetic
More informationThe Endocrine Society Guidelines
Vitamin D and Calcium Therapy: how much is enough DISCLOSURE Daniel D Bikle, MD, PhD Professor of Medicine VA Medical Center and University of California San Francisco Nothing to disclose RECOMMENDATIONS
More informationEmerging Areas Relating Vitamin D to Health
ILSI SEA Region Vit D Conference, Australia, June 2012 (www.ilsi.org/sea Region) Emerging Areas Relating Vitamin D to Health Peter R Ebeling MD FRACP NorthWest Academic Centre and Dept Endocrinology The
More informationUpdate on vitamin D. J Chris Gallagher Professor of Medicine and Endocrinology Creighton University Omaha,Nebraska USA
Update on vitamin D J Chris Gallagher Professor of Medicine and Endocrinology Creighton University Omaha,Nebraska 68131 USA Cali, Colombia 2016 definitions DRIs are the recommended dietary reference intakes
More informationJBMR. Serum 25-hydroxyvitamin D [25(OH)D] concentration may or
ORIGINAL ARTICLE JBMR Impact of Calcium and Vitamin D Insufficiencies on Serum Parathyroid Hormone and Bone Mineral Density: Analysis of the Fourth and Fifth Korea National Health and Nutrition Examination
More informationDietary Protein and Bone Health Emphasis: Animal Protein
USDA-ARS Human Nutrition Research Centers Dietary Protein and Bone Health Emphasis: Animal Protein Z.K. (Fariba) Roughead, PhD, RD Research Nutritionist USDA-ARS Grand Forks Human Nutrition Research Center
More informationGuideline for the investigation and management of osteoporosis. for hospitals and General Practice
Guideline for the investigation and management of osteoporosis for hospitals and General Practice Background Low bone density is an important risk factor for fracture. The aim of assessing bone density
More information9/26/2016. The Impact of Dietary Protein on the Musculoskeletal System. Research in dietary protein, musculoskeletal health and calcium economy
The Impact of Dietary Protein on the Musculoskeletal System Outline A. The musculoskeletal system and associated disorders Jessica D Bihuniak, PhD, RD Assistant Professor of Clinical Nutrition Department
More informationWho should receive calcium and vitamin D supplementation?
Age and Ageing Advance Access published August 8, 2012 Age and Ageing 2012; 0: 1 5 The Author 2012. Published by Oxford University Press on behalf of the British Geriatrics Society. doi: 10.1093/ageing/afs094
More informationSUMMARY OF PRODUCT CHARACTERISTICS. A 2.5ml single-dose bottle containing IU Cholecalciferol (equivalent to 625 micrograms vitamin D 3 )
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Fultium 25 000 IU Oral Solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION A 2.5ml single-dose bottle containing 25 000 IU Cholecalciferol
More informationGuideline for the Diagnosis and Management of Vitamin D Deficiency
Colchester Hospital University NHS Foundation Trust Guideline for the Diagnosis and Management of Vitamin D Deficiency As the symptoms and treatment doses can be different for adults and children, this
More informationBone Metabolism in Postmenopausal Women Influenced by the Metabolic Syndrome
Bone Metabolism in Postmenopausal Women Influenced by the Metabolic Syndrome Thomas et al. Nutrition Journal (2015) 14:99 DOI 10.1186/s12937-015-0092-2 RESEARCH Open Access Acute effect of a supplemented
More informationProphylactic treatment for osteoporosis: Student EBM Presentation
Prophylactic treatment for osteoporosis: Student EBM Presentation Callum Harris & Ealish Swift University of Oxford October 2015 Example patient JS is a 67 year old lady who needs to start taking long-term
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory OSTOCALCIUM TABLETS. Calcium and Phosphorus with Vitamin D3 Tablets
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory OSTOCALCIUM TABLETS Calcium and Phosphorus with Vitamin D3 Tablets QUALITATIVE AND QUANTITATIVE COMPOSITION Each uncoated
More informationVITAMIN D AND THE ATHLETE
VITAMIN D AND THE ATHLETE CONSIDERATIONS FOR THE PRACTITIONER Written by Bruce Hamilton, Qatar Vitamin D is a steroid hormone that has previously been given little attention, partially as a result of its
More informationSUMMARY OF THE PRODUCT CHARACTERISTICS
SUMMARY OF THE PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Recikalc-D forte 500 mg/ 800 IU chewable tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each chewable tablet contains calcium
More informationIn addition to bone health, emerging science reveals a non-skeletal benefit of vitamin D for several other health outcomes.
Vitamin D AT A GLANCE Introduction Vitamin D comprises a group of fat-soluble compounds that are essential for maintaining the mineral balance in the body. The vitamin D form synthesized in humans is called
More informationJMSCR Vol 06 Issue 12 Page December 2018
www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 79.54 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v6i12.157 A comparative study of two
More informationoriginal Se Hwa Kim 1), Tae Ho Kim 1) and Soo-Kyung Kim 2)
Endocrine Journal 2014, 61 (12), 1197-1204 original Effect of high parathyroid hormone level on bone mineral density in a vitamin D-sufficient population: Korea National Health and Nutrition Examination
More informationThe Relationship Between Serum 25(OH)D and Parathyroid Hormone Levels
CLINICAL RESEARCH STUDY The Relationship Between Serum 25(OH)D and Parathyroid Hormone Levels Walid Saliba, MD, MPH, a Ofra Barnett, PhD, a Hedy S. Rennert, MPH, a Idit Lavi, MA, a Gad Rennert, MD, PhD
More informationPROSTRAKAN v SHIRE. Calcichew-D 3 Forte journal advertisement CASE AUTH/1825/4/06
CASE AUTH/1825/4/06 PROSTRAKAN v SHIRE Calcichew-D 3 Forte journal advertisement ProStrakan complained about a journal advertisement for Calcichew-D 3 Forte (calcium carbonate, colecalciferol) issued by
More informationZeenat Ali, PGY3 Joseph Grisanti, MD June 7 th, 2012
A Randomized Open Label Trial to Evaluate the Efficacy of Different Dosage Forms of Vitamin D in Patients with Vitamin D Deficiency, and the Effect of Food on Vitamin D Absorption. Zeenat Ali, PGY3 Joseph
More informationOsteoporosis in Men Wendy Rosenthal PharmD. This program has been brought to you by PharmCon
Osteoporosis in Men Wendy Rosenthal PharmD This program has been brought to you by PharmCon Osteoporosis in Men Speaker: Dr. Wendy Rosenthal, President of MedOutcomes, will be the presenter for this webcast.
More informationManagement of postmenopausal osteoporosis
Management of postmenopausal osteoporosis Yeap SS, Hew FL, Chan SP, on behalf of the Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis,
More informationCalcium Marie Dunford, PhD, MD, Nutrition Consultant, Kingsburg, CA
Calcium Marie Dunford, PhD, MD, Nutrition Consultant, Kingsburg, CA Calcium is an essential mineral and a major nutrient needed for proper bone health. Absorption of calcium in adults is low. Vitamin D
More informationVitamin D Deficiency. Decreases renal calcium excretion. Increases intestinal absorption Calcium. Increases bone resorption of calcium
Vitamin D Deficiency Deborah Gordish, MD Assistant Professor of Clinical Internal Medicine Lead Physician Lewis Center Primary Care Associate Division Director General Internal Medicine The Ohio State
More information1. NAME OF THE MEDICINAL PRODUCT. Calciflex-D 3 Citron 500 mg/400 IU film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
1. NAME OF THE MEDICINAL PRODUCT Calciflex-D 3 Citron 500 mg/400 IU film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One tablet contains: Calcium carbonate equivalent to 500 mg calcium Cholecalciferol
More informationNatpara (parathyroid hormone) Prior Authorization with Quantity Limit Program Summary
Natpara (parathyroid hormone) Prior Authorization with Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 2 Available Product Indication Dosing and Administration Natpara (parathyroid hormone)
More informationAssessment and Treatment of Osteoporosis Professor T.Masud
Assessment and Treatment of Osteoporosis Professor T.Masud Nottingham University Hospitals NHS Trust University of Nottingham University of Derby University of Southern Denmark What is Osteoporosis? Osteoporosis
More informationVitamin D Hormone Du Jour
Vitamin D Hormone Du Jour J R Minkoff MD, FACP Endocrinology Clinical Professor of Family and Community Medicine UCSF Why Is Vitamin D Important? Musculo-skeletal effects Possible other effects Immunomodulatory
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory OSTOCALCIUM FORTE TABLETS
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory OSTOCALCIUM FORTE TABLETS Calcium and Phosphorus with Vitamin D3 Tablets QUALITATIVE AND QUANTITATIVE COMPOSITION Each
More informationThe Vitamin D Gap. Vitamin D intake guidelines were established to prevent. Estimating an adequate intake of vitamin D. FEATURE VITAMIN D GAP
The Vitamin D Gap Estimating an adequate intake of vitamin D. By Laurence Montgomery, ND and George Tardik, ND Vitamin D intake guidelines were established to prevent rickets in children and osteomalacia
More informationSerum vitamin D metabolites and intestinal calcium absorption efficiency in women 1 3
See corresponding editorial on page 673. Serum vitamin D metabolites and intestinal calcium absorption efficiency in women 1 3 John F Aloia, Ding-Geng Chen, James K Yeh, and Henian Chen ABSTRACT Background:
More informationApproach to a patient with hypercalcemia
Approach to a patient with hypercalcemia Ana-Maria Chindris, MD Division of Endocrinology Mayo Clinic Florida 2013 MFMER slide-1 Background Hypercalcemia is a problem frequently encountered in clinical
More informationBiochemical effects of calcium supplementation in postmenopausal women: influence of dietary calcium intake 1 3
Biochemical effects of calcium supplementation in postmenopausal women: influence of dietary calcium intake 1 3 Patrice Fardellone, Michel Brazier, Saïd Kamel, Jean Guéris, Anne-Marie Graulet, Jacques
More informationTHE SUNSHINE VITAMIN. Maureen Molini, MPH, RDN, CSSD University of Nevada Reno Student Health Services
THE SUNSHINE VITAMIN Maureen Molini, MPH, RDN, CSSD University of Nevada Reno Student Health Services Vitamin vs. Prohormone Technically not a vitamin since it isn t obtained solely through diet Synthesized
More informationCalcitriol is a white, crystalline compound, which occurs naturally in humans. It is soluble in organic solvents but practically insoluble in water.
Kosteo PRODUCT INFORMATION Name of the Medicine Calcitriol CAS 32222-06-3 The chemical name for calcitriol is 1,25-dihydroxycholecalciferol, the molecular formula is C 27 H 44 O 3. Calcitriol has a molecular
More informationProtocol GTC : A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients.
Protocol GTC-68-208: A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients. These results are supplied for informational purposes only.
More informationHypocalcemia 6/8/12. Normal value. Physiologic functions. Nephron a functional unit of kidney. Influencing factors in Calcium and Phosphate Balance
Normal value Hypocalcemia Serum calcium Total mg/dl Ionized mg/dl Cord blood 9.0 ~ 11.5 5.0 ~ 6.o New born (1 st 24 hrs) 9.0 ~ 10.6 4.3 ~ 5.1 24~ 48 hrs 7.0 ~12.0 4.0 ~4.7 Child 8.8 ~10.8 4.8 ~4.92 There
More informationClinical biochemistry of calcium and vitamin D
Clinical biochemistry of calcium and vitamin D Dr Andrew Day Consultant in Clinical Biochemistry and Metabolic Medicine University Hospitals Bristol NHS Trust e-mail: andrew.day@uhbristol.nhs.uk A 48-year
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Fultium 10 000 IU/ml Oral Drops, solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml oral solution contains: 10 000 IU Cholecalciferol
More informationParathyroid hormone (serum, plasma)
Parathyroid hormone (serum, plasma) 1 Name and description of analyte 1.1 Name of analyte Parathyroid hormone (PTH) 1.2 Alternative names Parathormone 1.3 NMLC code 1.4 Description of analyte PTH is an
More informationThe Bare Bones of Osteoporosis. Wendy Rosenthal, PharmD
The Bare Bones of Osteoporosis Wendy Rosenthal, PharmD Definition A systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase
More informationOsteoporosis and related fracture represent a significant
ORIGINAL ARTICLE Endocrine Care Effects of Calcium and Vitamin D Supplementation on Hip Bone Mineral Density and Calcium-Related Analytes in Elderly Ambulatory Australian Women: A Five-Year Randomized
More informationExcipient(s) with known effect: One tablet contains 1 mg aspartame (E951), 390 mg sorbitol (E420) and 0.7 mg sucrose
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Calcichew-D 3 Melon 500 mg/400 IU chewable tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One tablet contains: Calcium carbonate
More informationOral Alendronate Vs. Three-Monthly Iv Ibandronate In The Treatment Of Postmenopausal Osteoporosis
Oral Alendronate Vs. Three-Monthly Iv Ibandronate In The Treatment Of Postmenopausal Osteoporosis Miriam Silverberg A. Study Purpose and Rationale More than 70% of fractures in people after the age of
More informationAGE-RELATED HIP fracture is common in both men and
0021-972X/00/$03.00/0 Vol. 85, No. 9 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 2000 by The Endocrine Society Effect of Calcium or 25OH Vitamin D 3 Dietary Supplementation
More informationName of Policy: Boniva (Ibandronate Sodium) Infusion
Name of Policy: Boniva (Ibandronate Sodium) Infusion Policy #: 266 Latest Review Date: April 2010 Category: Pharmacology Policy Grade: Active Policy but no longer scheduled for regular literature reviews
More informationCalcium and vitamin D nutrition and bone disease of the elderly
Public Health Nutrition: 4(2B), 547±559 DOI: 10.1079/PHN2001140 Calcium and vitamin D nutrition and bone disease of the elderly C Gennari* Institute of Internal Medicine, University of Siena, Italy Abstract
More informationOsteoporosis and Nutrition Module 4 Speaking of Bones Osteoporosis For Health Professionals. Susan J Whiting University of Saskatchewan
Osteoporosis and Nutrition Module 4 Speaking of Bones Osteoporosis For Health Professionals Susan J Whiting University of Saskatchewan Learning Objectives Understand the 3 critical nutrients for bone:
More informationORIGINAL ARTICLE. R. A. Lyons & A. Johansen & S. Brophy & R. G. Newcombe & C. J. Phillips & B. Lervy & R. Evans & K. Wareham & M. D.
Osteoporos Int (2007) 18:811 818 DOI 10.1007/s00198-006-0309-5 ORIGINAL ARTICLE Preventing fractures among older people living in institutional care: a pragmatic randomised double blind placebo controlled
More information